2 completed, 1 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow David Peereboom: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence Pembrolizumab, SurVaxM, Sargramostim - Recurrent Glioblastoma | Phase 2 | Completed | David Peereboom | 41 | 2020-03-19 | 2024-08-28 |
| Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab - Glioblastoma | Phase 2 | Active not recruiting | David Peereboom | 90 | 2018-05-21 | 2025-02-28 |
| Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme erlotinib hydrochloride, temozolomide, radiation therapy - CNS Tumor, Adult | Phase 2 | Completed | David Peereboom | 27 | 2005-10-01 | 2012-12-06 |
Glioblastoma (3) · Central Nervous System Neoplasms (1) · Gliosarcoma (1)
Bevacizumab (1) · Erlotinib Hydrochloride (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Nivolumab (1) · Radiotherapy (1) · Temozolomide (1) · montanide ISA 51 (1) · pembrolizumab (1) · sargramostim (1)
United States (3)
P30CA043703 (1)